Jelleine
 | This article may need to be rewritten to comply with Wikipedia's quality standards. (January 2024) |
 | This article needs attention from an expert in Chemistry. Please add a reason or a talk parameter to this template to explain the issue with the article. (January 2024) |
Jelleine is a family of peptides, isolated from the royal jelly of Apis mellifera iberiensis, a subspecies of the honey bee. This new family has the potential to be used in the development of new drugs.[1]
Discovery
[edit]Jelleines were first isolated in 2004 by the research group of Professor Mario Sergio Palma at São Paulo State University, Brazil. First, he collected royal jelly from a group of honey bee larvae and purified the results by reverse phase, high-performance liquid chromatography. This purified royal jelly showed antimicrobial activity against different bacteria.[2] So far, four peptides have been found in this family, each one containing the carboxamide C-terminal.
Health benefits
[edit]Fungal spores lead to respiratory disease in more than 10 million people.[3] Compared to current antifungal agents, Jelleine has the potential to be a less toxic and more effective agent. Jelleine-I has been known to work against Candida albicans,[2] C. tropicalis, C. parapsilosis, and C. glabrata.[4] Jelleine-I causes damage that promotes microbial lysis. In addition, Jelleine has been shown to stimulate the formation of reactive oxygen species which improve its defense against Candida. In a test, Kunming mice were infected with C. Albicans. Then one hour after infection they were given different doses of jelleine-I over a period of 7 days. At the end of the experiment, the antifungal effect of Jelleine-I kept 60% of its group alive, while a separate group given Fluconazole only kept 40% alive and the untreated control group had a 100% mortality rate.[5]
Jelleine also has an antiparasitic ability against pathogens such as Leishmania. Most drugs administered are both toxic and prone to side effects.[6] Jelleine-I has low anti-leishmania activity, being able to stop promastigotes but having no effect on the amastigotes.[7]
Jelleine-I and its halogenated analogues show potential as an immunologic adjuvant in the treatment of colorectal cancer.[8] These peptides inhibit Fusobacterium nucleatum, an anaerobic bacterium of the oral microbiota that is highly active in the altered microecology of the gut and is closely associated with the initiation and progression of CRC.[9]
References
[edit]- ^ Lima, William Gustavo; Brito, Julio Cesar Moreira; Verly, Rodrigo Moreira; Lima, Maria Elena de (January 26, 2024). "Jelleine, a Family of Peptides Isolated from the Royal Jelly of the Honey Bees (Apis mellifera), as a Promising Prototype for New Medicines: A Narrative Review". Toxins. 16 (1): 24. doi:10.3390/toxins16010024. PMC 10819630. PMID 38251241.
- ^ a b Fontana, Renato; Mendes, Maria Anita; de Souza, Bibiana Monson; Konno, Katsuhiro; César, Lílian Mari Marcondes; Malaspina, Osmar; Palma, Mario Sergio (June 26, 2004). "Jelleines: a family of antimicrobial peptides from the Royal Jelly of honeybees (Apis mellifera)". Peptides. 25 (6): 919–928. doi:10.1016/j.peptides.2004.03.016. PMID 15203237. S2CID 6839870.
- ^ Rodrigues, Marcio L.; Nosanchuk, Joshua D. (February 26, 2020). "Fungal diseases as neglected pathogens: A wake-up call to public health officials". PLOS Neglected Tropical Diseases. 14 (2): e0007964. doi:10.1371/journal.pntd.0007964. PMC 7032689. PMID 32078635.
- ^ Kim, Seong Ryul; Choi, Kwang-Ho; Kim, Kee-Young; Kwon, Hye-Yong; Park, Seung-Won (September 28, 2020). "Development of a Novel Short Synthetic Antibacterial Peptide Derived from the Swallowtail Butterfly Papilio xuthus Larvae". Journal of Microbiology and Biotechnology. 30 (9): 1305–1309. doi:10.4014/jmb.2003.03009. PMC 9728235. PMID 32627752.
- ^ Jia, Fengjing; Wang, Jiayi; Peng, Jinxiu; Zhao, Ping; Kong, Ziqing; Wang, Kairong; Yan, Wenjin; Wang, Rui (February 1, 2018). "The in vitro, in vivo antifungal activity and the action mode of Jelleine-I against Candida species". Amino Acids. 50 (2): 229–239. doi:10.1007/s00726-017-2507-1. PMID 29101485. S2CID 254077869 – via Springer Link.
- ^ Ponte-Sucre, Alicia; Gamarro, Francisco; Dujardin, Jean-Claude; Barrett, Michael P.; López-Vélez, Rogelio; García-Hernández, Raquel; Pountain, Andrew W.; Mwenechanya, Roy; Papadopoulou, Barbara (2017). "Drug resistance and treatment failure in leishmaniasis: A 21st century challenge". Neglected Tropical Diseases. 11 (12): e0006052. doi:10.1371/journal.pntd.0006052. ISSN 1935-2735. PMC 5730103. PMID 29240765.
- ^ Zahedifard, Farnaz; Lee, Hyeryon; No, Joo Hwan; Salimi, Mona; Seyed, Negar; Asoodeh, Ahmad; Rafati, Sima (2020-02-01). "Comparative study of different forms of Jellein antimicrobial peptide on Leishmania parasite". Experimental Parasitology. 209: 107823. doi:10.1016/j.exppara.2019.107823. ISSN 0014-4894. PMID 31862270. S2CID 209434945.
- ^ Jia, Fengjing; Yu, Qun; Wang, Ruolei; Zhao, Ling; Yuan, Fuwen; Guo, Haidong; Shen, Yunhui; He, Feng (January 2023). "Optimized Antimicrobial Peptide Jelleine-I Derivative Br-J-I Inhibits Fusobacterium Nucleatum to Suppress Colorectal Cancer Progression". International Journal of Molecular Sciences. 24 (2): 1469. doi:10.3390/ijms24021469. ISSN 1422-0067. PMC 9865857. PMID 36674985.
- ^ Jia, Fengjing; Yu, Qun; Wang, Ruolei; Zhao, Ling; Yuan, Fuwen; Guo, Haidong; Shen, Yunhui; He, Feng (2023-01-11). "Optimized Antimicrobial Peptide Jelleine-I Derivative Br-J-I Inhibits Fusobacterium Nucleatum to Suppress Colorectal Cancer Progression". International Journal of Molecular Sciences. 24 (2): 1469. doi:10.3390/ijms24021469. ISSN 1422-0067. PMC 9865857. PMID 36674985.
 | This article needs additional or more specific categories. (January 2024) |